MX370795B - Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal. - Google Patents

Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal.

Info

Publication number
MX370795B
MX370795B MX2014015217A MX2014015217A MX370795B MX 370795 B MX370795 B MX 370795B MX 2014015217 A MX2014015217 A MX 2014015217A MX 2014015217 A MX2014015217 A MX 2014015217A MX 370795 B MX370795 B MX 370795B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
tryptophan
nicotinic acid
nicotinamide
intestinal microbiota
Prior art date
Application number
MX2014015217A
Other languages
English (en)
Other versions
MX2014015217A (es
Inventor
Georg Waetzig
Dirk Seegert
Original Assignee
Conaris Res Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Institute Ag filed Critical Conaris Res Institute Ag
Publication of MX2014015217A publication Critical patent/MX2014015217A/es
Publication of MX370795B publication Critical patent/MX370795B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una nueva composición farmacéutica que contiene ácido nicotínico, nicotinamina, compuestos relacionados con triptófano para influir de manera positiva en la microbiota intestinal. En ciertas modalidades, la composición farmacéutica es liberada parcial o completamente en el intestino delgado o el intestino grueso. La figura más representativa de la invención es la número 1.
MX2014015217A 2012-06-15 2013-06-14 Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal. MX370795B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012011890 2012-06-15
PCT/EP2013/062363 WO2013186355A1 (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota

Publications (2)

Publication Number Publication Date
MX2014015217A MX2014015217A (es) 2015-03-05
MX370795B true MX370795B (es) 2020-01-08

Family

ID=47002494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015217A MX370795B (es) 2012-06-15 2013-06-14 Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal.

Country Status (32)

Country Link
US (2) US10426765B2 (es)
EP (2) EP3831379B1 (es)
JP (3) JP6855165B2 (es)
KR (2) KR102211832B1 (es)
CN (2) CN108273064A (es)
AR (1) AR091465A1 (es)
AU (1) AU2013276451B2 (es)
BR (1) BR112014030835B1 (es)
CA (1) CA2876540C (es)
CY (1) CY1123999T1 (es)
DK (1) DK2861229T3 (es)
ES (1) ES2859758T3 (es)
HR (1) HRP20210090T1 (es)
HU (1) HUE053359T2 (es)
IL (1) IL236205B (es)
IN (1) IN2014DN10260A (es)
JO (1) JO3578B1 (es)
LT (1) LT2861229T (es)
MX (1) MX370795B (es)
NZ (1) NZ702297A (es)
PH (1) PH12014502744A1 (es)
PL (1) PL2861229T3 (es)
PT (1) PT2861229T (es)
RS (1) RS61288B1 (es)
RU (1) RU2657797C2 (es)
SA (1) SA113340643B1 (es)
SG (1) SG11201408251SA (es)
SI (1) SI2861229T1 (es)
SM (1) SMT202100248T1 (es)
TW (1) TWI624260B (es)
WO (1) WO2013186355A1 (es)
ZA (1) ZA201408922B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2861229T3 (da) 2012-06-15 2021-01-18 Conaris Res Institute Ag Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen
EP3003298B1 (en) * 2013-06-05 2024-03-20 The University Of British Columbia Anti-fibrogenic compounds, methods and uses thereof
US10456389B2 (en) * 2013-06-14 2019-10-29 Conaris Research Institute Ag Extended release nicotinamide formulation
EP2884282A1 (en) 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
WO2015086838A2 (en) 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
HUE048488T2 (hu) * 2013-12-13 2020-07-28 Conaris Res Institute Ag Nikotinsavat és/vagy nikotinamidot tartalmazó gyógyászati készítmény a vérlipid szint jótékony hatású befolyására történõ alkalmazásra a bélrendszeri mikrobióta módosításával
EP3107553B1 (en) * 2014-02-18 2021-12-01 Universitätsklinikum Jena Methods and compositions for intestinal microenvironment transfer
WO2015172801A1 (en) * 2014-05-12 2015-11-19 Unilever N.V. Niacinamide for inducing generation of antimicrobial peptides
CN105287561A (zh) * 2015-11-25 2016-02-03 上海交通大学医学院附属瑞金医院 一种治疗溃疡性结肠炎的药物组合物
CN115176998A (zh) 2016-04-14 2022-10-14 可劳迈戴斯有限公司 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸和烟碱基化合物衍生物在婴儿配方中的用途
BR112018071370A2 (pt) 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de mesalazina
TW201739455A (zh) 2016-04-19 2017-11-16 菲林公司 菸鹼醯胺的口服醫藥組成物
CN109718234A (zh) * 2017-10-31 2019-05-07 中国农业大学 L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用
JPWO2020166527A1 (ja) * 2019-02-12 2021-12-16 めぐみ 田中 乳幼児用飲食品、乳幼児の腸内環境の改善方法、及び乳幼児の免疫力の増強方法
CN113573777A (zh) 2019-03-28 2021-10-29 国立大学法人东北大学 癌的预防或治疗剂
CN113398130A (zh) * 2020-03-16 2021-09-17 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 烟酰胺用于预防和治疗胃肠道功能紊乱的用途
CN116635025A (zh) * 2020-11-27 2023-08-22 康纳里斯研究院股份公司 用于缩短covid-19和其他病毒感染患者的症状消退时间的烟酰胺、烟酰胺前体和烟酰胺代谢物及其组合物
US20230414599A1 (en) * 2020-11-27 2023-12-28 Conaris Research Institute Ag Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections
WO2023002939A1 (ja) * 2021-07-19 2023-01-26 明治ホールディングス株式会社 炎症性腸疾患の予防又は改善のための組成物、及び腸内細菌叢調節のための組成物
JP2025511241A (ja) * 2022-03-30 2025-04-15 コナリス リサーチ インスティテュート アクチェンゲゼルシャフト 感染症の１種又は複数の急性期後症状を予防又は低減するためのニコチンアミド、ニコチンアミド前駆体、ニコチンアミド代謝体又はその組合せを含む組成物
KR102789810B1 (ko) 2023-02-06 2025-03-31 한림대학교 산학협력단 아토피 피부염 진단용 바이오마커
CN117837697A (zh) * 2023-12-22 2024-04-09 汕头大学 一种烟酰胺的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE19524928A1 (de) * 1995-07-08 1997-01-09 Basf Ag Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5736532A (en) * 1996-02-14 1998-04-07 Furda; Ivan Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
JP2002533415A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびニコチン酸誘導体の組み合わせ
US6713057B1 (en) 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
GB0015242D0 (en) 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals
WO2002011725A1 (en) * 2000-08-08 2002-02-14 Shionogi & Co., Ltd. Inflammatory cytokine production inhibitors
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
AU2004314731B2 (en) 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US7326809B2 (en) 2004-05-27 2008-02-05 Antibe Therapeutics Inc. Salts of 4- or 5-aminosalicylic acid
EP1802287A2 (en) * 2004-09-27 2007-07-04 Sigmoid Biotechnologies Limited Minicapsule formulations
JPWO2007004613A1 (ja) 2005-07-01 2009-01-29 味の素株式会社 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤
DK2026651T3 (da) * 2006-03-08 2013-07-08 Cortria Corp Kombinationsterapi med ikke-selektive COX-inhibitorer til forebyggelse af COX-relaterede maveskader
ITMI20061932A1 (it) 2006-10-09 2008-04-10 Carlo Ghisalberti Complessi a trasferimento di carica per uso medicale
EP1935422A1 (en) * 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
WO2009051609A1 (en) * 2007-10-19 2009-04-23 Pardee Joel D Metabolic enhancement therapy
US20110104282A1 (en) * 2008-04-25 2011-05-05 Karolinska Institutet Innovations Ab New Therapy of Treatment of the Irritable Bowel Syndrome
CN102083466A (zh) * 2008-05-20 2011-06-01 科莱尼斯医疗公司 用于组合疗法的烟酸和nsaid
US20110123575A1 (en) * 2008-06-02 2011-05-26 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
JP5740306B2 (ja) 2008-10-03 2015-06-24 ドクトル ファルク ファルマ ゲーエムベーハー メサラミン顆粒を用いて腸疾患を治療するための組成物および方法
JP2011121889A (ja) 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP2012102054A (ja) 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
WO2012090224A1 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
DK2861229T3 (da) 2012-06-15 2021-01-18 Conaris Res Institute Ag Farmaceutisk sammensætning indeholdende nikotinsyre og/eller niko-tinamid og/eller tryptophan til positiv påvirkning af tarmmikrobiataen
US10456389B2 (en) 2013-06-14 2019-10-29 Conaris Research Institute Ag Extended release nicotinamide formulation
TW201739455A (zh) 2016-04-19 2017-11-16 菲林公司 菸鹼醯胺的口服醫藥組成物
US20230414599A1 (en) * 2020-11-27 2023-12-28 Conaris Research Institute Ag Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections

Also Published As

Publication number Publication date
RS61288B1 (sr) 2021-02-26
SMT202100248T1 (it) 2021-05-07
HK1204972A1 (en) 2015-12-11
US20150126462A1 (en) 2015-05-07
PH12014502744A1 (en) 2015-02-02
IL236205A0 (en) 2015-01-29
EP2861229A1 (en) 2015-04-22
ZA201408922B (en) 2016-10-26
PL2861229T3 (pl) 2021-08-09
KR20200011619A (ko) 2020-02-03
JP2015519388A (ja) 2015-07-09
RU2657797C2 (ru) 2018-06-15
MX2014015217A (es) 2015-03-05
AU2013276451A1 (en) 2015-01-15
TWI624260B (zh) 2018-05-21
US20200009124A1 (en) 2020-01-09
NZ702297A (en) 2016-11-25
BR112014030835B1 (pt) 2022-01-11
AU2013276451B2 (en) 2018-03-29
EP2861229B1 (en) 2020-12-23
HUE053359T2 (hu) 2021-06-28
CY1123999T1 (el) 2022-05-27
KR102211832B1 (ko) 2021-02-02
HRP20210090T1 (hr) 2021-03-05
US10426765B2 (en) 2019-10-01
KR20150021071A (ko) 2015-02-27
JP2019069972A (ja) 2019-05-09
EP3831379B1 (en) 2025-09-10
RU2014148239A (ru) 2016-08-10
CA2876540C (en) 2022-11-29
SG11201408251SA (en) 2015-01-29
DK2861229T3 (da) 2021-01-18
EP3831379A1 (en) 2021-06-09
SA113340643B1 (ar) 2019-10-06
ES2859758T3 (es) 2021-10-04
CA2876540A1 (en) 2013-12-19
CN108273064A (zh) 2018-07-13
LT2861229T (lt) 2021-01-25
BR112014030835A2 (pt) 2017-06-27
IL236205B (en) 2020-02-27
SI2861229T1 (sl) 2021-03-31
PT2861229T (pt) 2021-01-05
WO2013186355A1 (en) 2013-12-19
JP2022017332A (ja) 2022-01-25
IN2014DN10260A (es) 2015-08-07
TW201400116A (zh) 2014-01-01
JP6855165B2 (ja) 2021-04-07
CN104363907A (zh) 2015-02-18
AR091465A1 (es) 2015-02-04
JO3578B1 (ar) 2020-07-05

Similar Documents

Publication Publication Date Title
MX370795B (es) Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal.
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
EP2832851A4 (en) IMMORTALIZED STEM CELLS AND MEDICAL COMPOSITION AND MEDICAMENT WITH A PRODUCT THEREOF AS AN ACTIVE SUBSTANCE
UA110054C2 (uk) Розгалужені похідні 3-фенілпропіонової кислоти і їх застосування
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
HUE050146T2 (hu) Mikroorganizmust tartalmazó készítmény alkalmazása a vajsav, folsav vagy niacin béltermelés fokozására és/vagy a borostyánkõsav béltermelés csökkentésére
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
MX2019006878A (es) Uso de flecainida como un agente anti-conexina y metodo para potenciar los efectos de un farmaco psicotropico.
WO2015086843A3 (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
PE20142043A1 (es) Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112012020989A2 (pt) composições veterinárias
GEP201706621B (en) Benzamides
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
AR091495A1 (es) Sal de tipo camsilato
PH12016501059A1 (en) A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
EA201400444A1 (ru) Производные 2-оксопиперидинила

Legal Events

Date Code Title Description
FG Grant or registration